Daptomycin, a lipopeptide antibiotic, is one of the therapeutic options used for the treatment\nof vancomycin-resistant enterococci (VRE). Recently, the Clinical and Laboratory Standards Institute\n(CLSI) M100 30th edition has removed the susceptibility (S) breakpoint for Enterococcus faecium and\nreplaced it with a susceptible dose-dependent (SDD) breakpoint .....................
Loading....